Substituted 5,5′-diphenyl-2-thioxoimidazolidin-4-one as CB 1 cannabinoid receptor ligands: Synthesis and pharmacological evaluation

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2509-2517

  Muccioli, Giulio G ^a   Martin, Diana ^a   Scriba, Gerhard K E ^b   Poppitz, Wolfgang ^b   Poupaert, Jacques H ^a   Wouters, Johan ^c   Lambert, Didier M ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 ALLYL 5,5' BIS(4 BROMOPHENYL) 2 THIOXOIMIDAZOLIDIN 4 ONE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5,5' BIS(4 IODOPHENYL) 3 BUTYL 2 THIOXOIMIDAZOLIDIN 4 ONE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DML 20; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HYDANTOIN DERIVATIVE; LIGAND; OXYGEN; RADIOLIGAND; RIMONABANT; SLV 326; SULFUR; SULFUR 35; THIOHYDANTOIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRICAL POTENTIAL PARAMETERS; HUMAN; LIPOPHILICITY; NONHUMAN;

ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; IMIDAZOLIDINES; LIGANDS; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; THIOHYDANTOINS;

EID: 17144367660     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049263k     Document Type: Article

References (44)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
2. Gérard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 1991, 279, 129-134.
3. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
4. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
5. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97.
6. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83-87.
7. Ueda, N.; Yamanaka, K.; Yamamoto, S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous antiinflammatory substance. J. Biol. Chem. 2001, 276, 35552-35557.
8. Piomelli, D. The molecular logic of endocannabinoid signaling. Nat. Rev. Neurosci. 2003, 4, 873-84.
9. Calandra, B.; Portier, M.; Kerneis, A.; Delpech, M.; Carillon, C.; Le Fur, G.; Ferrara, P.; Shire, D. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 1999, 374, 445-455.
10. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R. Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 161-202.
11. 2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 2004, 53, 208-213.
12. Goutopoulos, A. and Makriyannis, A. From cannabis to cannabinergics: New therapeutic opportunities. Pharmacol. Ther. 2002, 95, 103-117.
13. 1 cannabinoid receptor signaling in Parkinson's disease. Curr. Opin. Pharmacol. 2003, 3, 54-61.
14. Muller-Vahl, K. R. Cannabinoids reduce symptoms of Tourette's syndrome. Expert. Opin. Pharmacother. 2003, 4, 1717-1725.
15. Lastres-Becker, I.; de Miguel, R.; De Petrocellis, L.; Makriyannis, A.; Di Marzo, V.; Fernandez-Ruiz, J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 2003, 84, 1097-1109.
16. Calignano, A.; Katona, I.; Desarnaud, F.; Giuffrida, A.; La Rana, G.; Mackie, K.; Freund, T. F.; Piomelli, D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000, 408, 96-101.
17. Song, Z. H.; Slowey, C. A. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol. Exp. Ther. 2000, 292, 136-139.
18. Pinto, L.; Izzo, A. A.; Cascio, M. G.; Bisogno, T.; Hospodar-Scott, K.; Brown, D. R.; Mascolo, N.; Di Marzo, V.; Capasso, F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002, 123, 227-234.
19. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244.
20. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Alonso, R.; Shire, D.; Congy, C.; Soubrie, P.; Breliere, J. C.; Le Fur, G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995, 56, 1941-1947.
21. 1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. 2003, 284, R345-353.
22. Colombo, G.; Agabio, R.; Diaz, G.; Lobina, C.; Reali, R.; Gessa, G. L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998, 63, PL113-117.
23. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002, 13, 451-63.
24. 1 cannabinoid receptor. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004, 310, 905-914.
25. 1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 1998, 284, 291-297.
26. 1-antagonistic properties. World Patent Organization WO0170700, 2001.
27. Lange, J. H.; Coolen, H. K.; van Stuivenberg, H. H.; Dijksman, J. A.; Herremans, A. H.; Ronken, E.; Keizer, H. G.; Tipker, K.; McCreary, A. C.; Veerman, W.; Wals, H. C.; Stork, B.; Verveer, P. C.; den Hartog, A. P.; de Jong, N. M.; Adolfs, T. J.; Hoogendoorn, J.; Kruse, C. G. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CBi cannabinoid receptor antagonists. J. Med. Chem. 2004, 47, 627-643.
28. 1 receptor antagonists related to SR141716. Bioorg. Med. Chem. Lett. 2004, 14, 1151-1154.
29. Jagerovic, N.; Hernandez-Folgado, L.; Alkorta, I.; Goya, P.; Navarro, M.; Serrano, A.; Rodriguez de Fonseca, F.; Dannert, M. T.; Alsasua, A.; Suardiaz, M.; Pascual, D.; Martin, M. I. Discovery of 5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J. Med. Chem. 2004, 47, 2939-2942.
30. Kanyonyo, M.; Govaerts, S. G.; Hermans, E.; Poupaert, J. H.; Lambert, D. M. 3-Alkyl-(5,5′-diphenyl)imidazolidinediones as new cannabinoid receptor ligands. Bioorg. Med. Chem. Lett. 1999, 9, 2233-2236.
31. 2 receptors. Eur. J. Pharmacol. 2004, 495, 43-53.
32. 1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling. J. Med. Chem. 2002, 45, 1748-1756. Erratum published in J. Med. Chem. 2002, 45, 4799.
33. 1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling. J. Med. Chem. 2002, 45, 1748-1756. Erratum published in J. Med. Chem. 2002, 45, 4799.
34. The 2-thioxoimidazolidin-4-one ring is also called thiohydantoin.
35. Ellsworth, T. J. 5,5-Diaryl-2-thiohydantoins and 5,5-diaryl N3-substituted 2-thiohydantoins as potential hypolipidemic agents. J. Med. Chem. 1986, 29, 855-859.
36. Muccioli, G. G.; Poupaert, J. H.; Wouters, J.; Norberg, B.; Poppitz, W.; Scriba, G. K. E.; Lambert, D. M. A rapid and efficient microwave-assisted synthesis of hydantoins and thiohydantoins. Tetrahedron 2003, 59, 1301-1307.
37. Kuebrich, J. P.; Schowen, R. L.; Wang, M.; Lupes, M. E. Mechanism of the benzoin condensation. J. Am. Chem. Soc. 1971, 93, 1214-1220.
38. Moore, M. L.; Crossley F. S. Organic Synthesis; Wiley: New York, 1963; Collect. Vol. III, pp 599-601.
39. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
40. 35S] GTPgammaS binding assay: Approaches and applications in pharmacology. Life Sci. 2003, 74, 489-508.
41. Easton, R. E.; Giesen, D. J.; Welch, A.; Cramer, C. J.; Truhlar, D. G. The MIDI! basis set for quantum mechanical calculations of molecular geometries and partial charges. Theor. Chim. Acta 1996, 93, 281-301.
42. Muccioli, G. G.; Wouters, J.; Poupaert, J. H.; Norberg, B.; Poppitz, W.; Scriba, G. K.; Lambert, D. M. Versatile access to benzhydryl-phenylureas through an unexpected rearrangement during microwave-enhanced synthesis of hydantoins. Org. Lett. 2003, 5, 3599-3602.
43. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
44. Bergman, D. L.; Laaksonen, L.; Laaksonen, A. Visualization of solvation structures in liquid mixtures. J. Mol. Graph. Model. 1997, 15, 301-306.